We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Dade Behring's Sales Rise in First Quarter

By Labmedica staff writers
Posted on 20 Apr 2001
For the first quarter of 2001, sales rose 13% over sales in the same period in 2000, reports Dade Behring (Deerfield, IL, USA). These results include a favorable one-time impact resulting from the company's adoption of a new accounting standard. Excluding this impact, sales were still up 7%. The growth was attributed to increased sales of the company's Dimension system and specialty product lines.

For the full year 2000, however, revenues were US$1.184 billion, about a 10% decrease from 1999. Dade Behring says revenues were affected by rising interest rates and a falling Euro as well as a decision to insource the distribution of two important product lines, which required a significant short-term use of cash.

"We are continuing to take aggressive, well-considered steps to address our financial performance, which was disappointing in 2000,” said Jim Reid-Anderson, president and CEO. "Already, we have eliminated several layers of management, consolidated support areas, and completed a significant global restructuring. These actions are generating encouraging results, and we are seeing revenue and earnings growth versus both our current financial plan and prior year in the first quarter of 2001.”


Related Links:
Dade Behring

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
8-Channel Pipette
SAPPHIRE 20–300 µL

Latest Industry News

WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
20 Apr 2001  |   Industry

BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
20 Apr 2001  |   Industry

Abbott Acquires Cancer-Screening Company Exact Sciences
20 Apr 2001  |   Industry